Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Actual. osteol ; 13(2): 104-115, Mayo - Ago. 2017. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-1117988

ABSTRACT

La osteonecrosis de maxilar asociada a aminobisfosfonatos (BRONJ) constituye un efecto secundario del tratamiento crónico con los más potentes. Un modelo experimental permitiría determinar la patogenia de dicha alteración. La oveja presenta características orales y del metabolismo óseo similar al humano y permite realizar manipulaciones bucales. Se evaluaron cambios clínicos, remodelación ósea y masa ósea maxilar en ovejas hembras adultas tratadas con zolendronato (ZOL), durante 22 meses y utilizando dosis equivalente al tratamiento de neoplasias. Seis ovariectomizadas (OVX) recibieron ZOL; 5 OVX y 4 SHAM (control) recibieron solución fisiológica. Al inicio, 4 y 22 meses se evaluó calcemia, fosfatemia, crosslaps (CTX) y fosfatasa alcalina ósea. Al final, se evaluó contenido mineral óseo de la hemimandíbula superior (CMO: mg/cm2). Al final del estudio, CTX disminuyó significativamente en ZOL (p<0,05) sin diferencias entre SHAM y OVX. En maxilar, los contenidos de Ca y P (g/g tejido) y CMO (g/cm2 ) disminuyeron en OVX vs. SHAM (p<0,05) y solo Ca y CMO respecto de ZOL (p<0,05). ZOL incrementó el contenido de Ca y CMO, mientras que el de P permaneció significativamente disminuido respecto de SHAM. La sobrevida en SHAM y OVX fue del 100% y en ZOL 77% (2 muertes); 2 ovejas del grupo ZOL presentaron necrosis de maxilar. Conclusiones: fue posible obtener desarrollo de BRONJ por tratamiento crónico con ZOL, el cual redujo notablemente la resorción y, según la relación Ca/P, posiblemente haya afectado la mineralización ósea. (AU)


Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a complication of chronic treatment with the most powerful aminobisphosphonates (BPs). An experimental animal model would allow to determine the pathogenesis of this complication. Ewes exhibit similar oral cavity characteristics and bone metabolism as humans, and they are suitable for oral cavity interventions. We examined herein the clinical manifestations, bone remodeling status, and maxillary bone mass in adult female ewes treated with zoledronate (ZOL) for 22 months. Six ovariectomized (OVX) ewes received ZOL; and 5 OVX and 4 SHAM animals received saline solution. At the start of the experiment, and at the 4 and 22 month-time points serum Ca, P, crosslaps (CTX), and bone alkaline phosphatase were measured. Bone mineral content (BMC) of the superior hemimandible was measured at the end of the experiment. At this time point, CTX was significantly decreased only in the ZOL group (p<0.05). Ca and P content (g/g tissue) and BMC in the mandible were significantly decreased in the OVX group compared to SHAM animals (p<0.05) and only Ca content and BMC were decreased when compared to ZOL (p<0.05). ZOL treatment increased the Ca content and BMC, whereas the P content remained low compared to the SHAM group (p<0.05). All ewes from the SHAM and OVX groups and 77% of the animals from the ZOL group survived until the end of the experiment, whereas two ewes of ZOL group exhibited BRONJ. Conclusion: under our experimental conditions, it was possible to induce BRONJ by the chronic ZOL administration, which in turn induced a high reduction in bone resorption as well as possibly impaired bone mineralization, based on the Ca/P ratio in the mandible. (AU)


Subject(s)
Animals , Diphosphonates/adverse effects , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Zoledronic Acid/adverse effects , Tooth Extraction , Bone Diseases, Metabolic/chemically induced , Sheep/metabolism , Sheep/blood , Biomarkers/blood , Bone Density/drug effects , Bone Remodeling/drug effects , Densitometry , Experimental Development , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Bisphosphonate-Associated Osteonecrosis of the Jaw/immunology , Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control , Zoledronic Acid/administration & dosage , Glucocorticoids/therapeutic use , Analgesics/therapeutic use , Ilium/cytology , Anesthetics, Dissociative/therapeutic use , Lidocaine/therapeutic use , Maxilla/cytology , Maxilla/drug effects , Maxilla/metabolism , Maxilla/diagnostic imaging , Anti-Bacterial Agents/therapeutic use
2.
Braz. oral res. (Online) ; 30(1): e107, 2016. tab, graf
Article in English | LILACS | ID: biblio-951964

ABSTRACT

Abstract There is little evidence on the long-term effects of pharmacological management in children undergoing dental treatment. This study aimed to assess children's behavior in consecutive dental sessions following oral rehabilitation using different pharmacological regimens for behavioral control. Participants were preschoolers who were previously treated for caries under one of the following: no sedative, oral sedation with midazolam, oral sedation with midazolam/ketamine, or general anesthesia. The children's behavior in the follow-up sessions was assessed using the Ohio State University Behavioral Rating Scale (OSUBRS); higher scores represented less cooperative behavior (range 5-20). Follow-up assessments were conducted on 50 children under four years old for up to 29 months. Data were analyzed by the Friedman/Wilcoxon tests and Cox regression model. OSUBRS mean (standard deviation) scores for the whole sample decreased from 11.9 (5.4) before treatment to 6.8 (3.2) at the final recall session (p < 0.001). Moderate sedation with midazolam (OR 2.9, 95%CI 1.2-6.9) or midazolam/ketamine (OR 4.3, 95%CI 1.6-11.4) improved children's future behavior. The general anesthesia group (n = 4) had a small sample size and the results should be considered with caution. Although invasive dental treatment negatively affected the child's behavior in the dental chair, they became more cooperative over time. Moderately sedated children showed better prospective behavior than those in the non-sedation group.


Subject(s)
Humans , Male , Female , Child, Preschool , Child Behavior/drug effects , Conscious Sedation/methods , Dental Care for Children/methods , Midazolam/therapeutic use , Proportional Hazards Models , Prospective Studies , Reproducibility of Results , Analysis of Variance , Age Factors , Treatment Outcome , Dental Anxiety/prevention & control , Statistics, Nonparametric , Dental Caries/therapy , Hypnotics and Sedatives/therapeutic use , Anesthesia, General/methods , Ketamine/therapeutic use , Anesthetics, Dissociative/therapeutic use
3.
Clinics ; 69(11): 777-786, 11/2014. tab, graf
Article in English | LILACS | ID: lil-731102

ABSTRACT

Premedication is important in pediatric anesthesia. This meta-analysis aimed to investigate the role of dexmedetomidine as a premedicant for pediatric patients. A systematic literature search was conducted to identify randomized controlled trials comparing dexmedetomidine premedication with midazolam or ketamine premedication or placebo in children. Two reviewers independently performed the study selection, quality assessment and data extraction. The original data were pooled for the meta-analysis with Review Manager 5. The main parameters investigated included satisfactory separation from parents, satisfactory mask induction, postoperative rescue analgesia, emergence agitation and postoperative nausea and vomiting. Thirteen randomized controlled trials involving 1190 patients were included. When compared with midazolam, premedication with dexmedetomidine resulted in an increase in satisfactory separation from parents (RD = 0.18, 95% CI: 0.06 to 0.30, p = 0.003) and a decrease in the use of postoperative rescue analgesia (RD = -0.19, 95% CI: -0.29 to -0.09, p = 0.0003). Children treated with dexmedetomidine had a lower heart rate before induction. The incidence of satisfactory mask induction, emergence agitation and PONV did not differ between the groups. Dexmedetomidine was superior in providing satisfactory intravenous cannulation compared to placebo. This meta-analysis suggests that dexmedetomidine is superior to midazolam premedication because it resulted in enhanced preoperative sedation and decreased postoperative pain. Additional studies are needed to evaluate the dosing schemes and long-term outcomes of dexmedetomidine premedication in pediatric anesthesia.


Subject(s)
Child , Child, Preschool , Female , Humans , Male , /therapeutic use , Anesthesia/methods , Dexmedetomidine/therapeutic use , Premedication/methods , Anesthetics, Dissociative/therapeutic use , Hypnotics and Sedatives/therapeutic use , Ketamine/therapeutic use , Midazolam/therapeutic use , Randomized Controlled Trials as Topic
5.
Acta cir. bras ; 21(4): 242-246, July-Aug. 2006. ilus
Article in English | LILACS | ID: lil-431843

ABSTRACT

OBJETIVO: Investigar, em ratos, o efeito da S(+)cetamina na histologia renal após hemorragia intra-operatória.MÉTODOS: Vinte ratos Wistar machos, anestesiados com pentobarbital sódico, foram divididos, aleatoriamente, em 2 grupos: G1 – controle (n=10) e G2 - S(+)cetamina (n=10), submetidos a hemorragia de 30% da volemia em 3 momentos (10% a cada 10 min) 60 min após anestesia. G2 recebeu S(+)cetamina, 15 mg. kg-1, i.m., 5 min após anestesia e 55 min antes do 1.º momento de hemorragia (M1). Foram monitorizadas a pressão arterial média (PAM), temperatura retal (T) e freqüência cardíaca. Os animais foram sacrificados (M4) 30 min após o 3.º momento de hemorragia (M3). Os rins e o sangue das hemorragias foram utilizados para estudo histológico e do hematócrito (Ht). RESULTADOS: Houve redução significativa da PAM, T e Ht. Na histologia, G1=G2 na dilatação tubular, congestão e necrose. A soma total dos escores foi significativamente diferente e G2>G1. CONCLUSÃO: Hemorragia e hipotensão determinaram alterações na histologia renal. O aumento da concentração sangüínea de catecolaminas provavelmente determinou escores mais altos de alterações histológicas com o uso de S(+)cetamina.


Subject(s)
Animals , Male , Rats , Anesthetics, Dissociative/pharmacology , Hemorrhage/physiopathology , Intraoperative Complications/physiopathology , Ischemia/physiopathology , Ketamine/pharmacology , Kidney/drug effects , Adjuvants, Anesthesia/pharmacology , Anesthetics, Dissociative/therapeutic use , Blood Pressure/drug effects , Blood Pressure/physiology , Blood Volume/drug effects , Blood Volume/physiology , Case-Control Studies , Disease Models, Animal , Hypotension/etiology , Hypotension/physiopathology , Hypovolemia/complications , Hypovolemia/physiopathology , Ketamine/therapeutic use , Kidney/blood supply , Kidney/physiopathology , Pentobarbital/pharmacology , Random Allocation , Rats, Wistar , Statistics, Nonparametric
6.
Braz. j. med. biol. res ; 34(9): 1217-1223, Sept. 2001. tab
Article in English | LILACS | ID: lil-290405

ABSTRACT

Ketamine is believed to reduce airway and pulmonary tissue resistance. The aim of the present study was to determine the effects of ketamine on the resistive, elastic and viscoelastic/inhomogeneous mechanical properties of the respiratory system, lungs and chest wall, and to relate the mechanical data to findings from histological lung analysis in normal animals. Fifteen adult male Wistar rats were assigned randomly to two groups: control (N = 7) and ketamine (N = 8). All animals were sedated (diazepam, 5 mg, ip) and anesthetized with pentobarbital sodium (20 mg/kg, ip) or ketamine (30 mg/kg, ip). The rats were paralyzed and ventilated mechanically. Ketamine increased lung viscoelastic/inhomogeneous pressure (26 percent) compared to the control group. Dynamic and static elastances were similar in both groups, but the difference was greater in the ketamine than in the control group. Lung morphometry demonstrated dilation of alveolar ducts and increased areas of alveolar collapse in the ketamine group. In conclusion, ketamine did not act at the airway level but acted at the lung periphery increasing mechanical inhomogeneities possibly resulting from dilation of distal airways and alveolar collapse


Subject(s)
Animals , Male , Rats , Anesthesia , Anesthetics, Dissociative/therapeutic use , Ketamine/therapeutic use , Respiratory Physiological Phenomena/drug effects , Adjuvants, Anesthesia/therapeutic use , Elasticity , Lung/pathology , Lung/physiology , Lung/physiopathology , Pentobarbital/therapeutic use , Random Allocation , Rats, Wistar , Respiratory System/pathology , Respiratory System/physiopathology , Thorax/pathology , Thorax/physiology , Thorax/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL